Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recipient-derived donor-origin CIK therapy for relapsed leukemia after allogeneic HSCT
ChiCTR-TNRC-11001348Phase 2Completed
- Sponsor
- Institute of Hematology of Union Hospital
- Start
- Jun 2011
- Modality
- Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of unmodified CIK and donor lymphocytes in Acute Leukaemia (3 arms), sponsored by Institute of Hematology of Union Hospital. Primary endpoints: leukemia-free survival, graft-versus-host disease incidence and 1 more. Started Jun 2011; status: completed.
02
Drugs
unmodified CIKdonor lymphocytes
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on ChiCTR-TNRC-11001348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-11001348.